MedTrace Logo

Study on Cognitive Disorders of Multiple Sclerosis

NCT01074619 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2012-09-03

No results posted yet for this study

Summary

The purpose of this study is to determine if memantine is effective in the treatment on cognitive disorders of Relapsing - Remitting multiple sclerosis. m

Conditions

Interventions

DRUG

Memantine

5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)

DRUG

Placebo

5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)

Sponsors & Collaborators

  • Ministry of Health, France

    collaborator OTHER_GOV

  • H. Lundbeck A/S

    collaborator INDUSTRY

  • University Hospital, Caen

    lead OTHER

Principal Investigators

  • Defer Gilles, Professor · Centre Hospitalier Universitaire de Caen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2011-03-31
Completion
2011-11-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01074619 on ClinicalTrials.gov